Summit Therapeutics (SMMT) Net Cash Flow (2020 - 2025)
Summit Therapeutics' Net Cash Flow history spans 6 years, with the latest figure at -$13.3 million for Q4 2025.
- For Q4 2025, Net Cash Flow fell 218.55% year-over-year to -$13.3 million; the TTM value through Dec 2025 reached $120.3 million, up 256.11%, while the annual FY2025 figure was $120.3 million, 256.11% up from the prior year.
- Net Cash Flow reached -$13.3 million in Q4 2025 per SMMT's latest filing, up from -$59.3 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $525.3 million in Q4 2022 to a low of -$578.1 million in Q1 2023.
- Average Net Cash Flow over 5 years is $8.0 million, with a median of -$3.6 million recorded in 2021.
- Peak YoY movement for Net Cash Flow: surged 6634.72% in 2022, then crashed 10024.15% in 2023.
- A 5-year view of Net Cash Flow shows it stood at -$8.0 million in 2021, then soared by 6634.72% to $525.3 million in 2022, then crashed by 90.98% to $47.4 million in 2023, then crashed by 76.36% to $11.2 million in 2024, then tumbled by 218.55% to -$13.3 million in 2025.
- Per Business Quant, the three most recent readings for SMMT's Net Cash Flow are -$13.3 million (Q4 2025), -$59.3 million (Q3 2025), and $86.3 million (Q2 2025).